Cutting-edge biotech company founded to target neurodegenerative diseases by improving disrupted physiological processes leading to dementia.
AstronauTx was created in 2019 with the goal of developing novel drugs to correct the disrupted physiology of the brain. Brandon is a Series A investor with the company using the funding to advance the company’s portfolio of first-in-class, small-molecule drugs, including a clinical study in patients with Alzheimer’s disease for its lead program.
Follow AstronauTx on LinkedIn to keep up to date on their progress.
